Open access peer-reviewed chapter

Hypogonadism in Male Sexual Dysfunction

Written By

Dana Stoian, Ioana Mozos, Marius Craina, Corina Paul, Iulian Velea, Adalbert Schiller and Mihaela Craciunescu

Submitted: December 28th, 2016 Reviewed: April 11th, 2017 Published: June 14th, 2017

DOI: 10.5772/intechopen.69107

Chapter metrics overview

1,420 Chapter Downloads

View Full Metrics


Normal testosterone level is influencing all the steps of the male psychosexual development: intrauterine neonatal and final psychosexual development.. At pubertal stage, the quality of testosterone secretion is conditioning the development of the mature male phenotype. In adult life, eugonadism sustains desire, arousal, determines spontaneous erections, facilitates stimulated erection, influencing the response rate to medication. Moreover, eugonadism sustain daydreaming and phantasies, both needed for a normal sexual life. The pathogenic mechanism of all these actions is presented. Talking about hypogonadism means not only the classical types of hypogonadism: due to classical testicular disease of central, hypothalamic and hypophysis disease, but also the partial testosterone deficiency induces by aging (late onset hypogonadism), weight increase (up to 30% of males with metabolic syndrome and 50% of males with diabetes) or secondary hypogonadism described in chronic use of steroids or after long exposure to stress, especially in young males. All these types of hypogonadism, that affect young, middle aged or old males will be presented separately. A therapeutic approach that is individualized for each type of hypogonadism, should consider positive and possible negative effects and all alternatives will be presented: life style changes, sustained weight loss, increase exercise, supplemental therapy, pro fertility treatment.


  • male sexual function
  • hypogonadism
  • late-onset hypogonadism
  • testosterone
  • supplemental treatment

1. Introduction

Testosterone is an essential hormone that influences part of sexual function in males.

Androgens directly influence the formation of male genital structures as an active process, start in the intrauterine life, sustain the phenotypic complete adult male pattern during development in puberty, and maintain the male phenotype during the entire life. Also androgens, together with other sexual steroids, do regulate sexual behavior, testosterone being the principal determinant of the sex drive not only in males but also in females. Male sexual response involves the presence of erection, a phenomenon influenced/sustained and modulated by testosterone levels. In these cases, the response rate to treatment is also dependent on the intratesticular testosterone. Psychosexual development is also conditioned by testosterone presence during childhood and puberty. Testosterone deficiency, regardless of inherited diseases, iatrogenic causes, metabolic disease or acquired causes, will impair normal sexual life and will condition the response to hormonal and non-hormonal treatment. Testosterone deficiency should be considered not only in the classical hypogonadism cases, with central or peripheral forms of disease, but also in the more frequent cause of subclinical, late onset of disease that affects half of the diabetic population, 30% of the metabolic syndrome male population and some of the elderly male population.


2. Role of testosterone in sexual function in males

Normal sexuality in both male and women presumes a normal phenotypic structure, sexual identity development and sexual orientation. Especially in males, testosterone influences all aspects of normal sexual function. In order to develop a normal sexual response, we need complete, congruent or not, sexual structures, sexual development and psychosexual components.

2.1. Testosterone effects in male sexualization: organic aspects

After the fertilization of the egg, the chromosomal sex is formed. According to the karyoptype [1], there are two ways of evolution:

The active way: In the presence of the sexual active chromosome Y, mainly the SRY gene, located on the short arm, favors the preprogrammed male gonadic development. The expression of SRY induces the organization of indifferent gonads to Sertoli cell differentiation [2], Antimullerian hormone production (AMH) [3], and secondary to testosterone synthesis from the Leydig cells [4]. The androgen presence will generate the evolution of Wolff tract structure (paracrine effect on the homonymous site) masculinization of the external genitals (weeks 12–16) and involution of Muller tract structures. Notably, testosterone in order to be active at the external genital ridge has to be converted to 5 α-dihydrotestosterone. Also, the testicular descent from the abdominal cavity is a dihydrotestosterone-dependent phenomenon. Normal testosterone levels, normal enzymatic apparatus and also normal testosterone receptor activity are needed to obtain the physiological effects.

The passive way: Feminization appears only in the absence of active Y chromosome expressing SRY gene, when regardless of the karyotype (46XX, 46 XY, 45X, 45 XX/45 XY), their evolution follows the free, automatic female gonad development, that only starts after the 3rd month of intra-gestational development [5]. In the absence of testosterone, there is an involution of the Wolff tract structures with a spontaneous, preprogramed differentiation of Muller tract structures: fallopian tubes, uterus and superior one-third of the vagina. Figure 1 summarizes the intrauterine changes in the genital area in both the sexes.

Figure 1.

Scheme of the somatosexual differentiation in the intrauterine period.

We can consider that the steroids have a major function in somatosexual development: organizational function—in the development phases, causing permanent changes in the body but also in the brain, and an activational function, active later in life, which will guide behavior.

The dismorphic brain changes are described by numerous studies. Testosterone is considered to be anxiolytic, anti-depressant and facilitates spatial abilities [6].

The postnatal somatosexual differentiation comprises small changes during early childhood. There are minimal somatic differences between sexes, steroid-independent: more female sex babies, boys are lesser maturated compared to girls, growth increase sooner in girls than boys, with increased size of extremities, increased mandibula, flattening of the trunk with important changes in cognition [7].

The puberty period represents the major second transformation period, both in genital and in nongenital spheres [8]. Secondary to the hypothalamus-hypophysis axis disinhibition, between 8 and 13 years of age in females and 9–13.5 years of age in boys, the production of sexual steroids increases dramatically and significant bodily changes appear secondary to exposure to sexual steroids. The somatic changes are measurable by the Tanner stage evaluation of secondary sexual characters (breast and pubic hair development in girls, external genitals and pubic hair in boys). In males, the following changes are described, all androgen dependent [9]: testosterone-dependent effects are increase in muscular mass, bone growth, growth of larynx and deepening of voice, inhibition of breast development, stimulation of spermatogenesis, whereas the dihydrotestosterone-dependent effects are phallic growth, development of pubic hair, and activity of sebaceous glands.

Table 1 summarizes the somatic changes observed in puberty, with the onset timing.

Male genderMean age (years)
Increase penis length11–12
Increase testes volume
Prostate growth12.5
Pubarche (P2)12–13
Growth spurt12–13
Sesamoid bone13
Accelerate increase in penis diameter13–14
Axillary hair (AH1)14–15
Pubarche (P4)14.5
Voice change14–15
Facial hair14–15
Pubarche (P5)15–16
Complete spermatogenesis16
Epiphyseal plate closure>17

Table 1.

Somatic changes in male puberty.

At the end of puberty, we have clear somatic differences between males and females, all sexual steroid-dependent [8, 9]. Notably, the full male pattern is present at the end of puberty, but the complete emotional evolution is not yet present. This is a high-risk period for sexual experiences.

During adulthood, eugonadism is important to maintain and sustain the previous organic changes. It has only a permissive role for maintaining normal sexual responses.

Regardless of diseases, aging is associated with physiological hormonal changes. There are several studies [1012] suggesting that aging is one of the major factors involved in sexual functional changes in males. There is physiological involution of all endocrine glands, with decreases in thyroid, adrenal and gonadal hormone production [12].

Many epidemiological studies describe a physiological decrease in total and free testosterone levels [1315]. Many changes are described with important sexual symptoms, similar to the presence of overt hypogonadism, with important diseases linked to this testosterone deficiency: bone demineralization [16], increased cardiovascular risk [17], frailty [18], weight gain [19], dyslipidemia [20] and increased general mortality [2123].

2.2. Testosterone role in male sexuality: psychosexual aspects

The psychosexual development is conditioned from the beginning in neonatal life.

Psychosexual differentiation refers to gender identity, respectively, self-identification as male or female, gender role, comprising different behavior in males and females, gender orientation, representing the choice of sexual partner, respectively cognitive differences [24]. Classically, gender identity was considered imprinted postnatally only by social attitudes, words, family dynamics, comparison of own body to pears, cultural differences, degree of exposure to nakedness [24], learning theory (gender identity is shaped by personal models and cultural influences, according to the interaction with parents), cognitive development theory (observation and imitation of behaviors appropriate for each gender), and biosocial interaction (society norms influencing subsequent behavior patterns in the childhood) [24].

Testosterone influences cell survival, anatomical connections and neurochemical activity, being responsible for brain differences in structure and function [25]. It is known that prenatal androgen exposure influences children’s sex-typed play behavior [26]. Genetic diseases with abnormal sexual steroid hormones can be used in the evaluation of sexual steroid impact on sexual identity: exposure to androgenic progestins increases male-typical behavior [27], and exposure to antiandrogenic products will decrease female-typical behaviors [28, 29]. There is a correlation between testosterone levels in maternal blood and amniotic fluid and sex-type behavior in childhood [30, 31]. Also, the new explanation for the “toy theory” is that androgen exposure favors interest for space movements, by influencing the development of visual fields [32, 33].

There is clear evidence that testosterone and dihydrotestosterone exposure can influence gender identity [33, 34]. Androgens have a facilitating and not a determinant role in gender identity development [35].

During childhood, psychosexual development is mainly socially dependent and not steroid-dependent: starting at approximately 1 year of age, boys and girls are aware of gender differences at an age of 2–3 years of their own gender, at 3 years of the behavior that belongs to the gender role, and from age 5 they play with the same gender peers. Before the age of 6 “sexual—genital” behaviors are reported but have no conscious significance, being just a pleasure action. After the age of 6 years, these behaviors are stable due to the juvenile pause. The development is free of androgen influence, due to the gonadostat inhibition, that stays till the spontaneous disinhibition of gonadotropic-gonadal axis. Still indirect effects are seen.

Puberty is a period with important changes in psychosexual behavior. In early adolescence, exposure to increased testosterone levels in boys will induce increased aggression and social dominance [36], whereas premature estrogen exposure in girls will favor mood changes [37]. During puberty, steroid hormones-related changes in the frontal lobe are different in boys and girls, favoring phonological skills in women and special skills in boys [38].

The hormonal and physical changes that occur during puberty also contribute in indirect ways to differences between adolescent boys and adolescent girls. In girls, secondary sexual changes will induce social reactions from peers, parents, teachers, and friends. Adolescence is associated with changing social roles, and there is good reason to believe that gender socialization intensifies at that time of life [39, 40].

During adolescence typical sexual behaviors will appear: in early adolescence physical changes dominate, with insecurity, sexual curiosity and exploration. Auto stimulation is reactivated, typical sexual in this case, different from the unconscious stimulation in the early childhood period. Androgens are the most important hormones that induce sexual drive [41]. Monogamously focused relationships, growing maturity, and responsibility characterize middle adolescence, and late adolescence is the period of beginning of mature sexuality and accumulation of sexual skills.

The relationship between testosterone and sexual behavior is more complex in humans than in animals, where sexual receptivity of the female and sexual interest in males is steroid-dependent [42]. In humans, there is a complex interference between genetic, hormonal, cultural, social, moral, and environmental influences.

In adults, testosterone sustains secondary sexual characters that were previously formed during puberty and directly influences all levels of sexual behavior:

Sexual fantasies are linked to testosterone levels, with a bimodal relationship, testosterone favors phantasies, and phantasies affect the testosterone levels [43]. Low testosterone levels in adult males change sexual interest even at the level of sexual fantasies [44, 45]. Even daydreaming is modulated by normal testosterone levels [45, 46].

Autostimulation and sexual actions are active behaviors, dependent on testosterone levels. The best evaluation of testosterone’s involvement in these behaviors is represented by different hypogonadism males, due to different causes [47, 48]. Autostimulation is considered a testosterone-dependent behavior; some hypogonadism questionnaires (ANDROTEST) consider impaired masturbation as a positive criterium for hypogonadism [49].

2.3. Testosterone implication in male sexual responses

The classic male sexual response as described by Masters’ and Johnson’ comprises the following event succession: excitement, plateau, orgasm, and resolution [42] corresponding to different levels of arousal.

The most important sign of excitement is the appearance of erection. There are three types of erections.

2.3.1. Erection

Stimulated erection is the most complicated and sensitive type of erection, appearing triggered by voluntary actions (kissing, touching, reading, seeing, and smelling), verbal or nonverbal message, anyhow after an interaction with a partner, appearing within few seconds after correct sexual stimulation, regardless of the type of stimulation. After stimulation, the brain releases stimulatory neurotransmitters (dopamine, nitric oxide, oxytocin, serotonin), from oxytoninergic, serotonergic, and dopaminergic neurons located in “erection centers” in the limbic system (paraventricular and supraoptic nuclei) that will generate proerectile impulses via the parasympathetic system [5053]. Parasympathetic impulses stimulate the spinal parasympathetic reflexogenic erection centers located at level S2–S4 [50] that will directly induce the vascular changes in the cavernous bodies, dilatation of arterioles, increased blow flow, decreased venous outflow due to compression of the subtunical venular plexuses, increase in oxygen pressure raising the penis, with subsidiary contraction of the ischiocavernosus muscles.

Testosterone influences erection both at central and at peripheral levels.

At CNS level, testosterone stimulates the synthesis, storage and release of proerectile neurotransmitters: dopamine, nitric oxide, and oxytocin [5456].

At spinal level, the somatic innervation (motoneurons) of bulbo- and ischiocavernous muscles is testosterone-dependent, meaning that testosterone influences both the rigidity of the erection and the orgasmic capacity [57, 58].

At the corpus cavernous level, testosterone influences parasympathetic nerves that generate oxid nitric, facilitating NO secretion [59]. Testosterone also influences the quality of cavernous muscle relaxation, influencing the expression of alpha adrenoreceptors [60, 61]. Also, androgen deprivation favors cavernous muscle smooth cells apoptosis [62].

Testosterone and its metabolites at both central and peripheral neural pathways are crucial for maintaining and restoring erectile capacity. The mechanism of enhanced erection with testosterone depends not only on the peripheral neural pathway but also on the central neural pathway.

  • Spontaneous erections are automatic, not controlled by a specific emotional content or response, being purely androgen-dependent. The mechanism of this erection is incompletely understood, but androgens play an important role [63, 64]. The role of this autonomous erection is nutritive for maintaining regular blood flow and oxygenation of the penis. Testosterone deficiency, depression, sleep apnea and altered REM phase sleep will impair this type of erection [65]. This type of erection is a very important diagnostic tool in the evaluation of erectile dysfunction and differentiation of organic from psychogenic erections.

  • Mechanical erection is the most “independent” type of erection to testosterone level. The somatic pathway is active in cases of stimulated central erections, but also independent, in local mechanical stimulation. Testosterone is indirectly influencing this type of erection only by changing the properties of the cavernous smooth muscle units.

Desire is not present in the classical male sexual response but still is a very important step in male sexuality. Desire is considered to consist of a drive—biological component, cultural component (wish) and motivational component (individual and relational psychology) [66]. Testosterone and other androgens sustain the drive component [67].


3. Testosterone deficiency

In all cases of hypogonadism, major sexual symptoms are described [6870]:

  • Alteration of sexual desire and arousal with a significant decrease in frequency of sexual activity

  • Decrease/altered quality of spontaneous erections

  • Partial alteration of psychic erections: decrease in frequency, amplitude, and rigidity

  • Alteration of orgasm and ejaculation proprieties

  • Altered response to phosphodiesterase-5 inhibitors

The implication of testosterone deficiency is clear, but the level of deficiency where symptoms appear is still debatable. Effects of testosterone on sexual function are dose-dependent up to a level close to the lower limit of normal range. From this threshold level, the effects are maximal. In cases with testosterone levels very close to this limit, the benefits of testosterone replacement are minimal. Below the threshold, the sexual function is impaired [67]. Different thresholds are described according to the wanted effect of testosterone [71]. Also the threshold value is variable and may increase with aging concerning sexual function, higher testosterone levels are needed with aging for the same result [72], with possible individual values, according to personal sensitivity [73]. The prevalence of sexual symptoms increases as testosterone levels decrease: low libido and vigor for values lower than 15 nmol/L (4.3 ng/mL), disturbed sleep at values less than 10 nmol/L, neurovegetative symptoms and erectile dysfunction at values less than 8 nmol/L (2.3 ng/mL) [71] and 1.5–2 ng/mL for nocturnal erection [74]. Other studies describe other testosterone values: below 8.5 nmol/L for erectile dysfunction, below 11 nmol/L for decreased frequency of morning erections and below 13 nmol/L for diminished vigor [75].

Because of all this individual variability and also because of different testosterone thresholds for different symptoms, there is still no consensus from the major professional societies about the definition of hypogonadism [7678].

3.1. Hypogonadism types

There are several types of hypogonadism that all lead to alteration of testosterone effects on target cells:

  • Primary hypogonadism is due to different testicular causes: chromosomal diseases (Klinefelter syndrome being the most frequent disease [79]) or testicular tumors with testosterone deficiency after treatment [80]. Orchitis, acquired anorchia, indiopathic testicular atrophy, congenital anorchia, 46 XY sexual development disorders, gonadal dysgenetic syndrome, Noonan Syndrome or LH receptor mutations are other causes of possible primary hypogonadism [76].

  • Secondary hypogonadism is due to central, hypothalamic or hypophyseal causes: functional or tumoral hyperprolactinemia, Kallmann syndrome, isolated LH deficiency, pituitary adenomas, autoimmune hypophysitis, iatrogenic pituitary insufficient (surgery, radiotherapy), CNS tumors Prader-Willi syndrome, congenital adrenal hyperplasia [76].

Both gonad and hypothalamus insufficiency: late onset hypogonadism due to aging or overweight or both is a typical mechanism that is seen in late onset hypogonadism. The hypothalamic pulsatile secretion of gonadotropin-releasing hormone is blunted, due to increased hypothalamic sensitivity to negative feedback from the peripheral androgens, with preservation of the responsiveness of the pituitary gonadotrophs. From a peripheral point of view, testicular volume as well as Leydig cell mass and reserve function are diminished. There is a reduced testosterone secretion with associated loss of nycthemeral variability [81]. The combined defects are responsible for a progressive decrease of testosterone level with 1–2% per year [14]. Chronic ill men, obesity and metabolic syndrome also determine testosterone deficiency in high percentages with a variable prevalence of 25% [82] up to 50% [83]. Taken all into consideration up to 20% of all men over 60 years of age have inappropriate testosterone levels [84].

  • Androgen receptor insensitivity/resistance is a very rare form of hypogonadism, due to total or partial androgen receptor insensitivity or 5-alpha reductase deficiency.

Regardless of type of hypogonadism, the clinical picture is dependent on the moment of onset of hypogonadism.

Prenatal testosterone deficiency will alter genital development, inducing all possible alteration of external genital aspects and formation: hypospadias, with different severity degrees, cryptorhidia, and ambiguous external genitals to female external genitals. These anatomical changes will impair future sexual function. The changes are irreversible and need surgical treatment for correction. The general surgical rule is to make the surgical treatment as soon as possible and to choose the gender, which is easier to be achieved with reconstructive treatment [85] but also in accordance to the intrauterine hormonal exposure. The goal is to complete the surgical correction till the age of 2 [86]. It is also important to evaluate, in the presence of nonfunctional/dysgenetic gonads, to evaluate the malignancy potential and to make the right treatment choices [87]. The major problems in many cases are unrecognized and undiagnosed at birth and are difficult to treat after 2 years of age because of organic causes and also due to the already established gender identity, gender role and sexual orientation. Testosterone replacement treatment is imperative, following the moment of physiological onset.

In cases of prepubertal testosterone deficiency, we will always observe a delayed puberty, defined in boys as no secondary sexual characters (increase in testes) before the age of 14 [88]. In severe causes of hypogonadism, the clinical picture is typical: small testes, cryptorhidia, gynecomastia, high-pitched voice, constant linear growth, eunuchoid habitus, sparse body and facial hair, decreased bone and muscle mass. From a sexuality point of view, these boys do not show sexual interest, have a decreased tendency of autostimulation, and have decreased phantasies and dreams. Untreated hypogonadism will affect all the levels of sexuality, with no normal development of sexuality. In the absence of normal androgen impregnation, there will be no erectile performance, altered sexual behavior, altered sense of well-being and globally affected sexual function [89]. If untreated, there will be no normal development of an adult male phenotype with serious impairment of sexual life.

Adult onset testosterone deficiency will induce different symptoms compared to previously mentioned forms of hypogonadism. The patients have normal developed genitals, normal developed secondary sexual characters, normal sexual function and behavior till the onset of hypogonadism. The clinical picture is dominated by metabolic and sexual symptoms. Sexual symptoms include loss of libido, erectile dysfunction, decrease in sexual phantasies, loss of body hair and hot flushes. Metabolic complications are loss of bone mass, sarcopenia, weight gain, increased body fat and increased vascular risk [9092].


4. Treatment principles in testosterone deficiency in males

4.1. Life style changes

Life style changes are important only in late-onset hypogonadism, significant weight reduction, decrease of body fat and regular exercise can increase endogenous testosterone level [93, 94]. Life style changes can improve testosterone balance, in absence of active hormonal replacement treatment [95, 96] but unfortunately significant weight loss of more than 10% is difficult to maintain [96]. This is the motif for which, in majority of cases, supplemental treatment is needed [97]. Even if possible results are interesting, in the testosterone normalization in diabetic and overweight patients with metabolic syndrome (what is this?), the compliance to sustained weight reduction is low in the long run, so decreased testosterone will reappear whenever a new weight increase occurs. Testosterone deficiency prevention is still a goal, with management and treatment of modifiable factors, such as weight control, regular sport activities, and decreased alcohol consumption, but in the majority of cases, it is difficult to sustain.

4.2. Testosterone supplemental therapy

Currently, testosterone supplemental therapy is the golden standard for management of testosterone deficiency symptoms, regardless of physical, psychological or sexual domains [98].

There is no clear consensus for an accepted lower limit of normal testosterone. Various guidelines for the diagnosis of hypogonadism are available: late-onset hypogonadism [78] (total testosterone < 8 nmol/L) should be treated with testosterone therapy, those with total testosterone level of 8–12 nmol/L and hypogonadal symptoms should be given a trial of testosterone replacement therapy, and those with total testosterone level > 12 nmol/L are not hypogonadal and should not be treated [99]. Other guidelines recommend treatment for values below 8 nmol/L only in cases of physical symptoms [76, 100].

Testosterone measurements should be measured in the morning, between 07 and 11 AM, on two different days, and both values should be low in order to confirm the testosterone deficiency. Total testosterone measurements are used in order to make a positive diagnosis.

Interventional studies have shown a beneficial effect of testosterone replacement therapy on insulin resistance [101]. The increase in insulin sensitivity is present in obese men [102, 103], patients with heart failure [104], with better glycemic controls in diabetic males under testosterone replacement therapy [105, 106].

There are some recommendations of active testosterone screening in special risk categories of males [76, 100, 107]:

  1. Type-2 diabetes mellitus

  2. Metabolic syndrome

  3. Moderate to severe chronic lung disease

  4. Osteoporosis

  5. History of infertility

  6. Treatment with steroids, opiates and anticonvulsants

  7. Alcohol abuse

  8. ED or loss of spontaneous erections

  9. Loss of sexual desire

The debate is around the type of symptoms that should be addressed for treatment. If correctly screened, with validated questionnaires, less than 5% of men with type-2 diabetes is asymptomatic, free of altered erectile performance, no present ED or altered arousal capacity [108].

The main concern in recommended testosterone replacement therapy is the vascular safety [109111] because of the suggestion of increased stroke risk, despite the reduction in major adverse cardiovascular events, as death, nonfatal myocardial infarction and stroke. Some studies suggest beneficial effects of testosterone on cardiovascular risk factors [112], low testosterone being associated with increased cardiac mortality [113, 114].

The benefits for the cardio metabolic risk profile are clear, not only in the direction of insulin sensitivity, as seen before, but untreated testosterone deficiency is also associated with a fourfold risk of developing type-2 diabetes in men [97]. Some studies suggest that testosterone replacement therapy induces favorable changes in total and low-density lipoprotein profile, lipoprotein, body fat composition and glycated hemoglobin levels [108, 115, 116].

Recent studies showed different results suggesting an increase in vascular events in the presence of testosterone supplemental therapy [117119]. Because of this opposing data, the FDA (Food and Drug Administration) still recommends that larger interventional studies are needed to have a definitive conclusion regarding testosterone treatment on cardiac safety [120]. Observational studies did not confirm the increase in cardiovascular events in long-term follow-up studies [121]. The EMA (European Medicines Agency) had agreed by consensus that there is no consistent evidence of an increased risk for heart problems with testosterone replacement in men lacking the hormone [122].

However, caution should be taken in cases with preexisting cardiovascular disease, especially in cases with increased hematocrit levels, due to increased primary thrombotic risk [123, 124].

Similar unresolved issues are seen when evaluating the associated presence of the following:

  • Obstructive sleep apnea, classically considered a contraindication for testosterone treatment, because of neutral studies, with no worsening of the disease [125127]

  • Lower urinary tract symptoms, which do not worsen under testosterone treatment, as classically considered [128130]

  • Congestive heart failure is still a relative contraindications for replacement treatment, but controversial, since excellent results are seen in testosterone treatment in cases with well controlled congestive heart failure [131]. Maybe untreated/uncontrolled heart failure should be considered as a contraindication.

  • Prostate safety: Prostate cancer is still a contraindication, but positive results start to emerge [76] with respect to lack of increased risk of prostate cancer under supplemental therapy. Also symptomatic hypogonadal men with localized prostate cancer, treated surgically, without active disease can be cautiously considered for testosterone therapy [132134]

Taking all these recommendations into consideration, testosterone has clear benefits regarding sexual health [97]. There is a significant effect on sexual desire, intercourse satisfaction and overall sexual satisfaction, when evaluated with FSFI questionnaire [135]. There are clear benefits on erectile function, with satisfactory sexual intercourses after at least 3 months of testosterone supplementation [135, 136]. Also, testosterone treatment, in hypogonadal men, improves the therapeutical response to phosphodiesterase-5 inhibitors [137], converting nonresponders to responders [138]. In general, testosterone supplementation has a positive effect on orgasmic and ejaculatory function [139]. Sexual interest appears after the first 3 weeks of use and reaches plateau in 6 weeks [136].

Except the late-onset hypogonadism, classical indications for testosterone supplementation are delayed puberty, Klinefelter syndrome, low bone mass in adult hypogonadism, hypopituitarism, and testicular dysgenesis. The therapy should be started at the appropriate age of puberty onset (in prepubertal forms of diseases) or after the clear diagnosis of hypogonadism (in postpubertal forms of diseases) [76]. Active follow-up should be performed in patients treated with testosterone supplementation therapy [76, 140]:

  • Symptoms response at every visit, minimum after 3 months of treatment, and then annually.

  • Formulation of specific adverse effects should be evaluated at each visit.

  • Testosterone level should be measured periodically, for a correct supplemental therapy at 3, 6 and 12 months after onset of the treatment.

  • All and each adverse event should be reported immediately.

  • Bone mineral density should be measured every 1–2 years

  • PSA measurement should be performed every 3 months, in the 1st year of treatment and then annually

  • Hematocrit measurement should be monitored at 3, 6 and 12 months and, thereafter, annually. Whenever the levels increase above 0.54, testosterone treatment should be discontinued.


5. Conclusion

When we think about hypogonadism, we should keep in mind not only the classical types of hypogonadism due to classical testicular disease of central, hypothalamic and hypophyseal disease, but we should also emphasize the partial testosterone deficiency that is described due to age increase (late-onset hypogonadism) or secondary to weight increase (up to 30% of males with metabolic syndrome and 50% of males with diabetes) or the secondary hypogonadism described after chronic use of steroids or after long exposure to stress, especially in young males. All these types of hypogonadism that affect young, middle-aged or old males are presented separately. The therapeutic approach should be individualized for each type of hypogonadism and should consider positive and possible negative effects. All alternatives are presented: life style changes, sustained weight loss, increased exercise, supplemental therapy and pro-fertility treatment.


  1. 1. Smith CA, Sinclair AH. The cell biology and molecular genetics of testis determination. Results and Problem in Cell Differentiation. 2000;28:23–52
  2. 2. Capel B. The battle of the sexes. Mechanisms of Development. 2000;92:89–10
  3. 3. Josso N, Cate RL, Picard JY, Vigier B, di Clemente N, Wilson C, Imbeaud S, Pepinsky RB, Guerrier D, Boussin L. Anti-Müllerian hormone: The jost factor. Recent Progress in Hormone Research. 1993;48:1–59
  4. 4. Siiteri PK, MacDonald PC. Role of extraglandular estrogen in human endocrinology. In: Greep RO, Astwood EB, editors. Handbook of Physiology, Vol. II. Female Reproductive System, Part I. Washington, DC: American Physiological Society; 1973. pp. 615–629
  5. 5. Grumbach MM, Conte FA. Disorders of sex differentiation. In: Wilson JD, Foster DW, Kronenberg HM, Larsen PR, editors. Williams Textbook of Endocrinology. 9th ed. Philadelphia: W.B. Saunders Co; 1998. pp. 1303–1425
  6. 6. Celec P, OStatnikova D, Hodosy J. On the effects of testosterone on brain behavioural functions. Frontiers in Neuroscience.2015;912. DOI: 10.3389/fnins.2015.00012
  7. 7. Hiort O, Thyen U, Holterhus PM. The basis of gender assignment in disorders of somatosexual differentiation. Hormone Research. 2005;64:18–22
  8. 8. Sex begins in the womb. Exporing the biological contributions to human health. Wizemann T, Pardue ML eds. Institute of Medicine (US) Comitee on Understanding the biology of sex and gender differences. Wizemann TM, Pardue ML, editors. Washingtopn (DC): National Academic Press (US): 2001
  9. 9. Molina P. Male reproductive system. In: Molina P, editor. Endocrine Physiology. 4th ed. Mc Graw Hill Co; 2013. USA
  10. 10. Feldman HA, Goldstein I, HAtzichristou, et al. Impotence and its medical and psychosocial correlates: Results of the Massachuses Male Aging Study. Journal of Urology. 1994;151:54–61
  11. 11. Braun M, Wassmer G, Klotz T, Reifenrath B, Mathers M, Engelmann U. Epidemiology of erectile dysfunction: Results of the Cologne Male Survey. International Journal of Impotence Research. 2000;12:305
  12. 12. Vermeulen A. Andropause. Maturitas. 2000;34:5–15
  13. 13. Harman SM, Metter EJ, Tobin JD, Pearson J, Blackman MR. Baltimore Longitudinal Study of Aging. Longitudinal effects of aging on serum total and free testosterone levels in healthy men. Baltimore Longitudinal Study of Aging. Journal of Clinical Endocrinology and Metabolism. 2001;86(2):724–731
  14. 14. Feldman HA, Longcope C, Derby CA, Johannes CB, Araujo AB, Coviello AD, Bremner WJ, McKinlay JB. Age trends in the level of serum testosterone and other hormones in middle-aged men: Longitudinal results from the Massachusetts male aging study. Journal of Clinical Endocrinology and Metabolism. 2002;87(2):589–598
  15. 15. Stanworth RD, Hugh Jones T. Testosterone for the aging male; current evidence and recommended practice. Clinical Interventions in Aging. 2008;3(1):25–44
  16. 16. Tran TS, Center JR, Seibel MJ, Eisman JA, Kushnir MM, Rockwood AL, Nyuyen TV. Relationship between serum testosterone and Fracture risk in men: A comparison of RIA and LC0 MS/MS. Clinical Chemistry. 2015;61(9):1182–1190
  17. 17. Traish AM. Testosterone therapy in men with testostosterone deficiency: Are we beyond the point of no return? Investigative and Clinical Urology. 2016;57(6):384–400
  18. 18. Ogawa S. Role of androgen in the elderly. Frailty and androgens. Clinical Calcium. 2013;23(8):1117–1122
  19. 19. Svartberg J, von Muhlen D, Schirmer H, Barrett-Connor E, Sundfjord J, Jorde R. Association of endogenous testosterone with blood pressure and left ventricular mass in men. The Tromsø Study. European Journal of Endocrinology. 2004;150(1):65–71
  20. 20. Naifar M, Rekik N, Messedi M, Chaabouni K, Lahiani A, Turk M, Abid M, Ayedi F, Jamoussi K. Male hypogonadism and metabolic syndrome. Andrologia. 2015;47(5):579–586
  21. 21. Santos MR, Sayegh AL, Groehs RV, Fonseca G, Trombetta IC, BAretto AC, Arap MA, Negrao CE, Middlekauff HR, Alves MJ. ARQUIVOS Brasileiros De Cardiologia. 2015;105(3):256–264
  22. 22. Pye SR, Huhtaniemi IT, Finn JD, Lee DM, O’Neil TW, Tajar A, BArtfai G, Boonen S, CAsanueva FF, Forti G, Giwercman A, Han TS, Kula K, Lean ME, Pendleton N, Punab M, Rutter MK, Vanderschueren D, Wu FC; EMAS Study Group. Late onset hypogonadism and mortality in aging male. Journal of Clinical Endocrinology & Metabolism. 2014;99(4):1357–1366
  23. 23. Muralledharan V, Marsh H, Kapoor D, Channer KS, Jones TH. Testosterone deficiency is associated with increased risk of mortality and testosterone replacement improves survival in men with type 2 diabetes. European Journal of Endocrinology. 2013;169(6):725–733
  24. 24. Masters W, Johnson V, Kolodny R, editors. Childhood Sexuality in in Human Sexuality. 5th ed. New York: Logman Inc.; 1995
  25. 25. Carthy MM, et al. Sexual differentiation of the brain: Mode, mechanisms, and meaning. In: Pfaff DW, et al., editors. Hormones, Brain and Behaviour. 2nd ed. Academic Press; US; 2009. pp. 1707–1744
  26. 26. Hines M. Sex-related variation in human behaviour and the brain. Trends in Cognitive Sciences. 2010;14(10):448–456
  27. 27. Reinisch JM. Prenatal exposure to synthetic progestin increases potential for aggression in humans. Science. 1981;211(4487):1171–1173
  28. 28. Ehrhardt AA, Money J. Progestin-induced hermaphroditism: IQ and psychosexual identity in a study of ten girls. The Journal of Sex Research. 1967;3:83–100
  29. 29. Ehrhardt AA, et al. Prenatal exposure to medroxyprogesterone acetate (MPA) in girls. Psychoneuroendocrinology. 1977;2:391–398
  30. 30. Hines M, et al. Testosterone during pregnancy and childhood gender role behavior: A longitudinal population study. Child Development. 2002;73:1678–1687
  31. 31. Alexander GM, Hines M. Sex differences in response to children’s toys in nonhuman primates (cercopithecus aethiops sabaeus). Evolution and Human Behaviour. 2002;23:467–479
  32. 32. Alexander GM. An evolutionary perspective of sex-typed toy preferences: Pink, blue, and the brain. Archives of Sexual Behaviour. 2003;32:7–14
  33. 33. Hines M. Brain Gender. Oxford University Press, UK; 2004
  34. 34. Hines M, et al. Androgen and psychosexual development: Core gender identity, sexual orientation and recalled childhood gender role behaviour in women and men with congenital adrenal hyperplasia (CAH). Journal of Sex Research. 2004;41:1–7
  35. 35. Ehrhardt AA, Baker SW. Fetal androgens, human central nervous system differentiation, and behaviour sex differences. In: New York. pp. 33–52
  36. 36. Brooks-Gunn J, Graber JA, Paikoff RL. Studying links between hormones and negative affect: Models and measures. Journal of Research on Adolescence. 1994;4:469–486
  37. 37. Buchanan CM, Eccles JS, Becker JB. Are adolescents the victims of raging hormones: Evidence for activational effects of hormones on moods and behaviour at adolescence. Psychological Bulletin. 1992;111:62–10
  38. 38. Spear LP. Neurobehavioral changes in adolescence. Current Directions in Psychologi cal Science. 2000;9:111–114
  39. 39. Crouter AC, Manke BA, McHale SM. The family context of gender intensification in early adolescence. Child Development. 1995; 66:317–329
  40. 40. Hill JP, Lynch ME. The intensification of gender-related role expectations during early adolescence. In: Brooks-Gunn J, Petersen AC, editors. Girls at Puberty: Biological and Psychosocial Perspectives. New York: Plenum Press; 1983. pp. 201–228
  41. 41. Kent A. Testosterone and sexual drive. Reviews in Obstetrics and Gynecology 2009;2(1):65–66
  42. 42. Masters WE, Johnson VE, Kolodny RC. Sexual physiology, in Human Sexuality, Masters 5th Ed. J, Johnson V, Kolodny R eds. 1995. New York: Longman Inc., US
  43. 43. Goldey KL, Avery LR, van Anders S. Sexual fantasies and gender/sex: A multi method approach with quantitative content analysis and hormonal response. Journal of Sex Research. 2014;5(8):917–931
  44. 44. Brett M.A., Roberts L.F., Johnson T.W. Eunuchs in contemporary society: Expectations, consequences, and adjustments to castration (part II) J Sex Med. 2007;4:946
  45. 45. Wibowo E, Wassersug R, Warkentin K. Impact of androgen deprivation therapy on sexual function: A response. Asian Journal of Andrology. 2012;14:793
  46. 46. Handy AB, Jackowich RA, Wibovo E, Johnson TW, Wassersug RJ. FGender preference in the sexual attraction, Fantasies and relationship of voluntarily castrated men. Sex Med 2016 4 (1): e51–59
  47. 47. Corona G, RAstrelli G, Ricca V, Jannini EA, Vignozzi L, Monani M, Sforza A, Forti G, Mannucci E, Maggi M. Risk factors associated with primary and secondary reduced libido in male patients with sexual dysfunction. Journal of Sexual Medicine. 2013; 10(4):1074–1089
  48. 48. Lejeune H, Huyghe E, Droupy S. Hypoactive sexual desire and testosterone deficiency in men. Progress of Urology. 2013;23(9):621–628
  49. 49. Corona G, Rastrelli G, Vignozzi L, Mannucci E, Maggi M. How to recognize late onset hypogonadism in men wuth sexual dysfunction. Asian Journal of Andrology. 2012;14(2):251–259
  50. 50. Dean RC, Lue TF. Physiology of penile erection and pathophysiology of erectile dysfunction. Urologic Clinics of North America. 2005;32(4):379
  51. 51. Stoleru S, Redoute J, Costes N, et al. Brain processing of visual sexual stimuli in men with hypoactive sexual desire disorder. Psychiatry Research. 2003;124:67
  52. 52. Mouras H, Stoleru S, Bittoun J, et al. Brain processing of visual sexual stimuli in healthy men: A functional magnetic resonance imaging study. Neuroimage. 2003;20:855
  53. 53. Arnow BA, Desmond JE, Banner LL, et al. Brain activation and sexual arousal in healthy, heterosexual males. Brain. 2002;125:1014
  54. 54. Burnett AL. Neurophysiology of erectile function: Androgenic effects. Journal of Andrology. 2003;24:S2-S5
  55. 55. Saenz de Tejada I. Further commentary: Physiology of erectile function and pathophysiology of erectile dysfunction. In: Lue TF, Basson R, Rosen R, Giuliano F, Khoury S, Montorsi F, editors. The Second International Consultation on Sexual Medicine: Sexual Medicine-Sexual dysfunctions in Men and Women. Plymouth: Plymbridge Distributors Ltd.; 2004. pp. 289–343
  56. 56. Purves Tyson TD, Handelsman DJ, Double KL, Owens SJ, Bustamante S, Weickert CS. Testosterone regulation of sex steroid related mRNAs and dopamine-related mRNAs in adolescent male rat substantia nigra. BMC Neuroscience. 2012;13:95. DOI: 10.1186/1471-2202-12-95
  57. 57. Meisel RL, Sachs BD. The physiology of male sexual behaviour. In: Knobil E, Neill JGS, Greenwald GS, Markert CL, Pfaff DW, editors. The Physiology of Reproduction. Vol. 2. New York: Raven Press; 1994. pp. 3–107
  58. 58. Mills TM, Reilly CM, Lewis RW. Androgens and penile erection: A review. Journal of Andrology. 1996;17:633–638
  59. 59. Baba K, Yajima M, Carrier S. Effect of testosterone on nitric oxide synthetase-containing nerve fibres and intracavernous pressure in rat corpus cavernosum. International Journal of Impotence Research. 1994;6:S1. D6
  60. 60. Takahashi Y, Hirata Y, Yokoyama S, Ishii N, Nunes L, Lue TF, Tanagho EA. Loss of penile erectile response to intracavernous injection of acetylcholine in castrated dog. The Tohoku Journal of Experimental Medicine. 1991;163:85–91
  61. 61. Zvara P, Sioufi R, Schipper HM, Begin LR, Brock GB. Nitric oxide mediated erectile activity is a testosterone dependent event: A rat erection model. International Journal of Impotence Research. 1995;7:209–219
  62. 62. Shabsigh R. The effect of testosterone on the cavernous tissue and erectile function. World Journal of Urology. 1997;15(1):21–26
  63. 63. Mann K, Sohn M. Spontaneous noctrumnal erection physiologic and clinical applications. Somnologie. 2005;9(3):119–126
  64. 64. Carani C, Bancroft J, Granata A, Del Rio G, Marrama P. testosterone and erectile function, nocturnal penile tumescence and rigidity, and erectile response to visual erotic stimuli in hypogonadal and Eugonadal men. Psychoneuroendrocrinology. 1992;17(6):647–654
  65. 65. Husnu T, Ersoz A, Bulent E, Tacettin O, Remzi A, Bulent A, Aydin M. Obstructive sleep apnea syndrome and erectile dysfunction: Does long term continuous positive pressure improve erections. African Health Sciences. 2015;15(1):171–179
  66. 66. Levine SB. The nature of sexual desire: A clinician’s perspective. Archives of Sexual Behavior. 2003;32(3):279–285
  67. 67. Morales A, Buvat J, Gooren LJ, Guay AT, Kaufmann JM, Kim YC, Tan HM, Torres LO. Endocrine aspects of men sexual dysfunction. In: Lue TF, Basson R, Rosen R, Guiliano F, Khoury S, Montorsi F, editors. Sexual Medicine: Sexual Dysfunction in Men and Women 2nd International Consultation on Sexual Dysfunction. Paris: Health Publication; 2004
  68. 68. Barkin J. Erectile dysfunction and hypogonadism. Canadian Journal of Urology. 2011;18(S2):7
  69. 69. Buvat J, Bou Jaoude G. Significance of hypogonadism in erectile dysfunction. World Journal of Urology. 2006;24(6):657–667
  70. 70. Morales A, Biuvat J, Gooren LJ, Guat AT, Kaufman JM, Tan HM, Torres LO. Endocrine aspects of sexual dysfunction in men. The Journal of Sexual Medicine. 2004;1(1):69–81
  71. 71. Zitzmann M, Faber S, Nieschlag E. Association of specific symptoms and metabolic risk with serum testosterone in older men. Journal of Clinical Endocrinology & Metabolism. 2006;91(11):4335–4343
  72. 72. Gray PB, Singh AB, Woodhouse LJ, et al. Dose-dependent effects of testosterone on sexual function, mood, and visuospatial cognition in older men. Journal of Clinical Endocrinology & Metabolism. 2005;90:3838–3846
  73. 73. Kelleher S, Conway AJ, Handelsman DJ. Blood testosterone thersold for androgen deficiency symptoms. Journal of Clinical Endocrinology & Metabolism. 2004;69(8):3813–3817
  74. 74. Carani C, Zini D, Baldini A, et al. Testosterone and prolactin: behavioural and psychophysiological approaches in men. In: Bancroft J, et al., editors. The Pharmacology of Sexual Function and Dysfunction. Amsterdam: Elsevier Science; 1995. pp. 145–150
  75. 75. Vesper HW. Interlaboratory comparison study of serum total testosterone measurements performed by mass spectrometry methods. Steroids. 2009;74(6):498–503
  76. 76. Dohle GR, Arver S, Bettocchi C, Joones TH, Kliesch S, Punab M. Guidelines on Male Hypogonadism. EAU. 2015. Available from:
  77. 77. Petak SV, Nankin HR, Spark RF, swerdloff RS, Rodriquez Rihgau. AACE Guidelines for evaluation and treatment of hypogonadism in adult male patients. Endocrine Practice. 2002;8(6):439–456
  78. 78. Bhasin S, Cunningham GR, Hayes FJ, Matsumoto AM, Snyder PJ, Swerdloff RS, Montori VM. Testosterone therapy in men with androgen deficiency syndromes: an endocrine clinical practice guide. 2010;95(6): 2536-2559
  79. 79. Bojesen A, et al. Prenatal and postnatal prevalence of Klinefelter syndrome: A national registry study. Journal of Clinical Endocrinology & Metabolism. 2003;88(2):622–626
  80. 80. Eberhart J, et al. Risk factors for postreatment hypogonadism in testicular cancer patients. European Journal of Endocrinology. 2008;158(4):561–570
  81. 81. Mahmoud A, Comhaire FH. Mechanisms of disease: Late-onset hypogonadism. Nature Clinical Practice Urology. 2006;3(8):430–438
  82. 82. Dandona P, Dhindsa S. hypogonadotropic hypogonadism in type 2 diabetes and obesity. JCEM. 2011; 96(9):2643–2651
  83. 83. Kapoor D, Aldred H, Clark S, Channer KS, Jones H. Clinical and biochemical assessment of hypogonadism in men with type 2 diabetes. Diabetes Care. 2007;30(4):911–917
  84. 84. Kaufmann J, Vermeulen A. The decline of androgens levels in elderly men and its clinical implications. Endocrine Reviews. 2005;26:833–876
  85. 85. Moshiri M, Chapman MD, Fechner PY, Dubinsky TJ, Shnohavorian M, Osman S, Bharga P, Katz DS. Evaluation an management of disorders of sexual development: multidisciplinary approach to a complex diagnosis. Radiographics 2012;32(6):1599-1618
  86. 86. Göllü G, Yildiz RV, Bingol-Kologlu M, et al. Ambiguous genitalia: An overview of 17 years’ experience. Journal of Pediatric Surgery. 2007;42(5):840–844
  87. 87. Looijenga LHJ, Hersmus R, Oosterhuis JW, Cools M, Drop SL, Wolffenbuttel KP. Tumor risk in disorders of sex development (DSD). Best Practice & Research: Clinical Endocrinology & Metabolism. 2007;21(3):480–495
  88. 88. Palmert MR, Dunkel L. Delaued puberty. The New England Journal of Medicine. 2012;366:4430453
  89. 89. Kumar P, Kumar N, Thakur DS, Patidar A. Male Hypogonadism symptoms and treatment. Journal of Advanced Pharmaceutical Technology & Research. 2010;1(3):297–301
  90. 90. Laughin A, Barret-Connor E, Bergstrom J. Low serum testosterone and mortality in older men. Journal of Clinical Endocrinology & Metabolism. 2008;93:68–75
  91. 91. Travosin TG, Shackelton R, Arujo AB. The natural history of symptomatic androgen deficiency in men: Onset, progression, and spontaneous remission. Journal of the American Geriatrics Society. 2008;56:831–839
  92. 92. Arujo AB, Esche GR, Kepulian V, et al. Prevalence of symptomatic androgen deficiency in men. Journal of Clinical Endocrinology & Metabolism. 2007;92:4241–4247
  93. 93. Kumagai H, Zempo-Miyaki A, Yoshikawa T, Tsujimoto T, Tanaka K, Maeda S. Lifestyle modification increases serum testosterone level and decrease central blood pressure in overweight and obese men. Endocrine Journal. 2015;62(95):423–430
  94. 94. Bobadilla L, Aberg K, Johnson M, Shirtcliff EA. Experiences in the military may impact dual axis neuroendocrine processes in veterans. Developmental Psychobiology. 2015;57(6):719–730
  95. 95. Moro T, Tinsley G, Bianco A, Marcolin G, Pacelli QF, Battaglia G, Palma A, Gentil P, Neri M, Paoli A. Effects of eight weeks of time-restricted feeding (16/8) on basal metabolism, maximal strength, body composition, inflammation, and cardiovascular risk factors in resistance-trained males. Journal of Translational Medicine. 2016;14(1):290
  96. 96. Cunnnigham GR. Testosterone and metabolic syndrome. Asian Journal of Andrology. 2015;17(2):192–196
  97. 97. Hackett G. An update on the role of testosterone replacement therapy in the management of hypogonadism. Therapeutic Advances in Irology. 2016;8(2):147–160
  98. 98. Hissaues S. Contemporary perspective and management of testosterone deficiency: Modifiable factors and variable management. International Journal of Urology. 2015;22(12):1084–1095
  99. 99. Nieschlag E, Swerdloff R, Behre HM, Gooren LJ, Kaufman JM, Legros JJ, Lunenfeld B, Morley JE, Schulman C, Wang C, Weidner W, Wu FC: Investigation, treatment and monitoring of late-onset hypogonadism in males: ISA, ISSAM, and EAU recommendations. International Journal of Andrology. 2005;28:125–127
  100. 100. Wylie R, Rees M, Hacket G, Anderson R, Bouloux P, Cust M. Androgens, health and sexuality in women and men. Maturitars. 2010;67:275–289
  101. 101. Simon D, Charles MA, Lahlou N, Nahoul K, Oppert JM, Gouault-Heilmann M, Lemort N, Thibult N, Joubert E, Balkau B, Eschwege E. Androgen therapy improves insulin sensitivity and decreases leptin level in healthy adult men with low plasma total testosterone. Diabetes Care. 2001;24:2149–2151
  102. 102. Marin P, Holmang S, Jonsson L, Sjostrom L, Kvist H, Holm G, Lindstedt G, Bjorntorp P. The effects of testosterone treatment on body composition and metabolism in middle-aged obese men. International Journal of Obesity and Related Metabolic Disorders. 1992;16:991–997
  103. 103. Marin P, Krotkiewski M, Bjorntorp P. Androgen treatment of middle-aged, obese men: Effects on metabolism, muscle and adipose tissues. European Journal of Medicinal. 1992;1:329–336
  104. 104. Malkin CJ, Jones TH, Channer KS. The effect of testosterone on insulin sensitivity in men with heart failure. European Journal of Heart Failure. 2007;9:40–50
  105. 105. Kapoor D, Goodwin E, Channer KS, Jones TH. Testosterone replacement therapy improves insulin resistance, glycaemic control, visceral adiposity and hypercholesterolemia in hypogonadal men with type 2 diabetes. European Journal of Endocrinology. 2006;154:899–906
  106. 106. Boyanov MA, Boneva Z, Christov VG. Testosterone supplementation in men with type 2 diabetes, visceral obesity and partial androgen deficiency. Aging Male. 2003;6:1–7
  107. 107. Home P, MAnt J, Diaz J, Turner C Guideline development group. Management of type 2 diabetes summary of update NICE guidance. British Medical Journal. 2008;336:1306–1308
  108. 108. Hacket G, Cole N, Bhartia M, Wilkinson P, Raju J, Wilkinson P. Testosterone replacement therapy improves metabolic parameters in hypogonadal men with type 2 diabetes but not in men with coexisting depression the BLAST study. Journal of Sexual Medicine. 2014;11:840–856
  109. 109. Anderson JL, May HT, Lappe DL, Bair T, Le V, Carquist JF, Muhlestein JB. Impact of testosterone replacement therapy in myocardial infarction, stroke and death in men with low testosterone concentrations in an integrated health care system. American Journal of Cardiology. 2016;117(5):794–799
  110. 110. Kloner RA, Carson C, Dobs A, Kopecky S, Mohler ER. Testosterone and cardiovascular disease. Journal of the American College of Cardiology. 2016;67(5):5450557
  111. 111. Traish AM, Zitzmann M. The complex and multifactorial relationship between testosterone deficiency obesity and vascular disease. Reviews in Endocrine and Metabolic Disorders. 2015;16(3):249–268
  112. 112. Jones TH. Testosterone deficiency: A risk factor for cardiovascular disease? Trends in Endocrinology and Metabolism. 2010;21(8):496–503
  113. 113. Corona G. Hypogonadism as a risk factor for cardiovascular mortality in men. Meta analytic study. European Journal of Endocrinology. 2011;165(5):687–701
  114. 114. Malkin CJ. Low serum testosterone and increased mortality in men with coronary heart disease. Heart. 2010;96(22):1821–1825
  115. 115. Traish A, Haider A, Doros G, Saad F. Long term testosterone therapy in hypogonadal men ameliorates elements of metabolic syndrome: An observational, long term registry study. International Journal of Clinical Practice. 2014;68:314–329
  116. 116. Saad F, Yassin A, Haider A, Doros G, Gooren L. Elderly men over 65 years o age with late onset hypogonadism benefits as much from testosterone treatment as do younger men. Jorrean Journal of Urology. 2015;56:310–317
  117. 117. Basaria S. Adverse events associated with testosterone administration. The New England Journal of Medicine. 2010;363(2):109–122
  118. 118. Finkle WD. Increase risk of nonfatal myocardial infarction following testosterone therapy prescription in men. PLoS One. 2014;9(1):e85805
  119. 119. Vigen R. Association of testosterone therapy with mortality, myocardial infarction, and stroke in men with low testosterone levels. Journal of the American Medical Association. 2013;310(17):1829–1836
  120. 120. FDA. Advisory committee industry briefing document. Testosterone therapy. Bone, reproductive and urologic drug advisory committee and the drug safety and risk management advisory committee. 2014
  121. 121. Baillargeon J. Risk of myocardial infarction in older men receiving testosterone therapy. Annals of Pharmacotherapy. 2014;48(9):1138–1144
  122. 122. Review of testosterone containing medicine started. EMA/209962/2014. European Medicine Agency 2014. Available from:
  123. 123. Gagnon DR. Hematocrit and risk of cardiovascular disease – the Framingham study: A 34-year follow up. American Heart Journal. 1994;127(3):674–682
  124. 124. Boffetta PA. U shaped relationship between haematocrit and mortality in a large prospective cohort study. International Journal of Epidemiology. 2013;42(2):601–615
  125. 125. Hildreth KL, Barry DW, Moreau KL, et al. Effects of testosterone and progressive resistance exercise in healthy, highly functioning older men with low normal testosterone levels. Journal of Clinical Endocrinology & Metabolism. 2013;98(5):1891–1990
  126. 126. Hoyos CM, Killock R, Yee BJ. Effects of testosterone therapy on sleep and breathing in obese men with severe obstructive sleep apnoea: A randomized controlled trial. Clinical Endocrinology (Oxford). 2012;77(4):599–607
  127. 127. Killick R, Wang D, Hoyos CM. The effects of testosterone on ventilatory responses in men with obstructive slpee apnea: A randomised, placebo controlled trial. Journal of Sleep Research. 2013;22(3):331–336
  128. 128. Kalichenko SY, Tishova YA, Maskhlaya GJ. Effects of testosterone supplementation on markers of the metabolic syndrome and inflammation in hypogonadal men with metabolic syndrome: The double blind placebo controlled Moscow study. Clinical Endocrinology (Oxford). 2010;73(5):602–612
  129. 129. Srinivas Shankar U, Roberts SA, Connolly MJ. Effects of testosterone on muscle strength, physical activity, body composition, and quality of life in intermediate frail and frail elderly men: A randomized, double blind, placebo controlled study. Journal of Clinical Endocrinology & Metabolism. 2010;95(5):639–650
  130. 130. Tan WS, Low WY, Ng CJ. Efficacy and safety on long acting intramuscular testosterone undecanoate in aging men: A randomised controlled study. BJU International. 2013;111(7):1130–1140
  131. 131. Stout M, tew GA, Doll H. Testosterone therapy during exercise rehabilitation in males with chronic heart failure who have low testosterone status: A double blind randomized controlled feasibility study. American Heart Journal. 2012;164(6):893–901
  132. 132. Morgentaler A. Testosterone therapy in men with prostate cancer: Scientific and ethical considerations. Journal of Urology. 2009;181(3):972–979
  133. 133. Aversa A. Cardiometabolic complications after androgen deprivation therapy in men with prostate cancer: Effects of a 3 years intermittent testosterone supplementation. Frontiers in Endocrinology (Laussanne). 2012;3:17
  134. 134. Kaufman JM. Androgen replacement after curative radical prostatectomy for prostate cancer in hypogonadal men. Journal of Urology. 2004;172(3):920–922
  135. 135. Moon du G. The efficacy and safety of testosterone undecanoate in testosterone deficiency in Korea: A multicentre prospective study. Journal of Sexual Medicine. 2010;7(6):2253–2260
  136. 136. Saad F. Onset of effects of testosterone treatment and time span until maximum effects are achieved. European Journal of Endocrinology. 2011;165(5):675–685
  137. 137. Corona G. Testosterone supplementation and sexual function. A meta analysis study. Journal of Sexual Medicine. 2014;11(6):1577–1592
  138. 138. Buvat J, Montorsi F, Maggi M, Porsst H, Kaipia A., Colson M. Hypogonadal men nonresponders to the PDE5 inhibitor Tadalafil benefit from normalization of testosterone gelin the treatment of erectile dysfunction. Journal of Sexual Medicine. 2011;8:284–293
  139. 139. Boloña ER, Uraga MV, Haddad RM, Tracz MJ, Sideras K, Kennedy CC, Caples SM, Erwin PJ, Montori VM. Testosterone use in men with sexual dysfunction: A systematic review and meta-analysis of randomized placebo-controlled trials. Mayo Clinic Proceedings. 2007;82:20–28
  140. 140. Dandona P, Rosenberg MT. A practical guide to male hypogonadism in the primary care setting. The International Journal of Clinical Practice. 2010;64(6):682–696

Written By

Dana Stoian, Ioana Mozos, Marius Craina, Corina Paul, Iulian Velea, Adalbert Schiller and Mihaela Craciunescu

Submitted: December 28th, 2016 Reviewed: April 11th, 2017 Published: June 14th, 2017